Covalon Technologies Second Quarter 2025 Earnings: EPS: CA$0.02 (vs CA$0.059 in 2Q 2024)

Covalon Technologies (CVE:COV) Second Quarter 2025 Results

Key Financial Results

• Revenue: CA$7.59m (down 9.8% from 2Q 2024).
• Net income: CA$429.1k (down 71% from 2Q 2024).
• Profit margin: 5.7% (down from 17% in 2Q 2024). The decrease in margin was primarily driven by lower revenue.
• EPS: CA$0.02 (down from CA$0.059 in 2Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Covalon Technologies Earnings Insights

Looking ahead, revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 62% growth forecast for the Biotechs industry in Canada.

Performance of the Canadian Biotechs industry.

The company's shares are down 7.7% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Covalon Technologies you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.